JATT vs. EPIX, PRLD, CDXC, GBIO, GTHX, CHRS, MCRB, XBIT, VTYX, and PBYI
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include ESSA Pharma (EPIX), Prelude Therapeutics (PRLD), ChromaDex (CDXC), Generation Bio (GBIO), G1 Therapeutics (GTHX), Coherus BioSciences (CHRS), Seres Therapeutics (MCRB), XBiotech (XBIT), Ventyx Biosciences (VTYX), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.
JATT Acquisition (NYSE:JATT) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
ESSA Pharma's return on equity of -19.46% beat JATT Acquisition's return on equity.
48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 14.7% of ESSA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, ESSA Pharma had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for ESSA Pharma and 0 mentions for JATT Acquisition. ESSA Pharma's average media sentiment score of 1.17 beat JATT Acquisition's score of 0.00 indicating that ESSA Pharma is being referred to more favorably in the news media.
ESSA Pharma received 349 more outperform votes than JATT Acquisition when rated by MarketBeat users.
ESSA Pharma has a consensus price target of $16.50, suggesting a potential upside of 208.99%. Given ESSA Pharma's higher possible upside, analysts plainly believe ESSA Pharma is more favorable than JATT Acquisition.
Summary
ESSA Pharma beats JATT Acquisition on 7 of the 10 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
